Perceptive Advisors acquires 700,000 OBIO shares (+15.2% increase) at $2.75 while stock down 63.8% from 52-week high, amid unprofitability and declining revenue.
Perceptive Advisors LLC, a 10% shareholder, purchased 700,000 shares at $2.75 on 2025-08-01, increasing holdings to 5.29M shares. The transaction occurs with Orchestra BioMed trading at $2.67 (current price), down 63.8% from its 52-week high of $7.38. The company faces material headwinds: latest quarterly revenue is $868,000, full-year net income was negative at $-18.8M, and annual revenue growth is negative at -4.4%. The insider's cross-ticker track record shows a mixed pattern—14 prior buys averaged +122.0% 30-day returns, but this outsized performance does not extend reliably to single-ticker performance and may reflect selection bias across multiple positions. The fundamental deterioration (negative profitability, revenue decline) combined with the substantial price markdown from peak valuations raises questions about whether this represents accumulation at distressed levels or conviction in a turnaround narrative that remains unvalidated by current operating metrics.